Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: functional and morphological properties.
A negative 72-h fast is usually considered to preclude the diagnosis of insulinoma. The aim of this study was to describe the functional and morphological properties of two exceptional patients with an insulinoma who had exhibited pre-operatively a negative 72-h fast. Despite the ability of tumor cells to turn off insulin secretion in response to low plasma glucose during 72 h of fasting, hyperinsulinemic hypoglycemia occurred in both patients in response to stimulation by classical secretagogues. Pre-operatively, both patients underwent oral and iv glucose challenge tests and iv glucagon stimulation test. Insulin secretion was rapidly stimulated by these secretagogues to an exaggerated extent and thereby caused hypoglycemia due to an insulin mass effect. In contrast to the common functional features during suppression and stimulation tests, the tumors differed widely with regard to insulin and proinsulin response to calcium during ASVS tests and morphological properties. In patient 1, the immunohistochemical proinsulin distribution pattern resembled that of normal beta-cells, i.e. the staining was restricted to the perinuclear area; insulin and proinsulin were not stimulated by calcium during the ASVS test. In patient 2, the proinsulin staining pattern was abnormal, i.e. proinsulin was also found in the periphery of tumor cells; insulin and proinsulin were stimulated by calcium. We conclude that normal or exaggerated rather than defective glucose sensing may explain hypoglycemia in these exceptional insulinoma patients. Different functional characteristics of these tumors can be correlated with distinct morphological properties.
Wiesli
P
P
Department of Internal Medicine, Division of Endocrinology and Diabetes, Institute for Diagnostic Radiology, University Hospital of Zurich, Zurich, Switzerland. peter.wiesli@DIM.usz.ch
Schmid
C
C
Perren
A
A
Pfammatter
T
T
Spinas
G A
GA
Keller
U
U
D000368:Aged; D000369:Aged, 80 and over; D002118:Calcium / Q000008:administration & dosage / Q000494:pharmacology; D005215:Fasting / Q000097:blood*; D005260:Female; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology*; D005947:Glucose; D005951:Glucose Tolerance Test; D006503:Hepatic Veins; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000378:metabolism; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007340:Insulinoma / Q000097:blood / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D010190:Pancreatic Neoplasms / Q000097:blood / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D013997:Time Factors
D007004:Hypoglycemic Agents; D007328:Insulin; D005934:Glucagon; D005947:Glucose; D002118:Calcium